TrialsgrambetaRCTs are beautiful

TB-PRACTECAL

2022

Short All-Oral Regimens for Rifampicin-Resistant TB

In 552 patients with rifampicin-resistant tuberculosis, a 24-week regimen of bedaquiline, pretomanid, linezolid and moxifloxacin improved favourable outcome at 72 weeks compared with the 9–20-month standard of care.

Result

Favourable outcome at 72 weeks
Absolute difference
37 points
NNT
3
Effect estimate

risk difference-3796.6% CI -53 to -22

Absolute difference and NNT are derived from the event rates.

Also reported: mITT: 89 % vs 52 % favourable ; noninferior, better safety with BPaLM.

Original publication
Subtopic
MDR-TB
Design
Open-label RCT
Enrolled
301 patients
Relevance
Practice-defining: a trial the field needs to know.
Source
Nyang'wa BT, et al. N Engl J Med. 2022;387(25):2331-2343.doi 10.1056/NEJMoa2117166

Discussion & critique

Generational shift in MDR-TB care: 6-month all-oral BPaLM replaces 18–24-month injectable-based regimens. Now the WHO-preferred therapy for MDR-TB without fluoroquinolone resistance.

Discussed in podcasts